Latest news
China’s PD-1/VEGF Bet Challenges the Lung Cancer Backbone
HARMONi-6 showed an overall survival advantage for ivonescimab plus chemotherapy over PD-1 plus chemotherapy in first-line squamous NSCLC, putting China-origin oncology innovation directly into the global standard-of-care debate.
Parkinson’s Research Moves From Tracking Progression to Defining Biology
MS Monitoring Starts Moving Beyond the MRI Bottleneck
Latin America Challenges the Dementia Biomarker Evidence Gap
China’s Alzheimer’s Blood-Test Rollout Turns Diagnosis Into an Access Market
Alzheimer’s Blood Testing Moves Toward Routine Care
AI Mental Health Support Becomes a Governance Test
Alzheimer’s Drugs Force NICE Back Into the Value Debate
Europe Starts Treating Brain Health as System Resilience
Oncology Trials Still Do Not Match the Patients They Will Treat
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.